Don't Miss

Biosimilar Index is a comprehensive drug intelligence service which provides robust, dynamically updated and highly-detailed data, analysis and insight on the status of all known biosimilar development projects worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type, combining on-going tracking of biosimilar developments with expert analysis and insight on the commercial impact. Learn more.

Sanofi, Regeneron say PCSK9 inhibitor alirocumab meets main goal of nine late-stage studies